Answers are grounded in this paper and cite their sources.
SUMMARY The management of central nervous system bleeding emergencies is a common clinical challenge. The most common scenarios include spontaneous intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (SAH), traumatic epidural and subdural hematomas, hemorrhagic infarction and spinal epidural bleeding. A recent phase II clinical trial demonstrated that ultra‐early hemostatic therapy with recombinant activated factor VII (rFVIIa) limits ongoing bleeding, reduces hematoma volume and improves survival and functional outcome, despite a small increase in the risk of thromboembolic complications. A definitive phase III study (the FAST [rFVIIa in Acute Hemorrhagic Stroke Treatment] Trial) is now in progress to confirm these results. A pilot trial of continuous rFVIIa infusion to prevent re‐bleeding after SAH was stopped because of concerns regarding ischemic complications related to vasospasm. Intravenous vitamin K and fresh frozen plasma are the mainstays of therapy for coagulopathic intracranial bleeding, but normalization of coagulation can take many hours, and outcomes are often unsatisfactory. Successful off‐label use of rFVIIa to stabilize patients with warfarin‐associated ICH and subdural hematoma or to expedite emergency surgery has been reported, but questions remain regarding the optimal dose for this indication. Clinical trials are urgently needed to confirm that rFVIIa can safely arrest active bleeding and expedite life‐saving emergency neurosurgical procedures in anticoagulated patients with intracranial hemorrhage.
No takes yet. Share an insight, caveat, or question.
Rincón et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: